Herbert Smith Freehills advises sole sponsor and overall coordinators on Cutia Therapeutics' Hong Kong IPO 史密夫斐尔律师事务所作为独家保荐人和整体协调人律师为科笛集团香港上市提供法律服务

Leading international law firm Herbert Smith Freehills has advised the sole sponsor and the overall coordinators on Cutia Therapeutics (02487.HK)'s mainboard listing on the Hong Kong Stock Exchange. The listing is sponsored by China International Capital Corporation Hong Kong Securities Limited as the sole sponsor. China International Capital Corporation Hong Kong Securities Limited, Deutsche Bank AG, Hong Kong Branch, CLSA Limited, Huatai Financial Holdings (Hong Kong) Limited, CMB International Capital Limited and BOCI Asia Limited are the overall coordinators of the Global Offering.

国际领先的律师事务所史密夫斐尔于科笛集团(02487.HK)在香港联交所主板上市的项目中担任独家保荐人和整体协调人的律师并提供法律服务。在该上市项目中，中金公司担任独家保荐人，中金公司、德意志银行、中信里昂、华泰国际、招商国际和中银国际担任整体协调人。

Cutia Therapeutics is an R&D-driven, dermatology-focused biopharmaceutical company. The company focuses on broader dermatology treatment and care therapeutic areas, including localised adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Cutia Therapeutics listed on 12 June 2023.

"We are delighted to have worked with Cutia Therapeutics, a leading biopharmaceutical company, on its successful listing on the Hong Kong Stock Exchange,” said Hong Kong partner Matt Emsley. "We congratulate Cutia Therapeutics, the sole sponsor and the overall coordinators on this successful IPO and wish them continued success."

"We thank our clients for their trust in us – we are delighted to work with them on this and other global capital markets matters," said senior registered foreign lawyer (New York, USA)* Stanley Xie.

Herbert Smith Freehills leads the legal market in advising sponsors and underwriters on Hong Kong IPOs, with over 20 IPOs successfully listed on the Hong Kong Stock Exchange in the past two years.

Matt, Stanley and senior registered foreign lawyer (New York, USA) Jin Kong jointly led the team advising the sole sponsor and the overall coordinators, assisted by registered foreign lawyer (New York, USA) Ariel Lin, senior associate Maisie Ko, associates Cyrus Wong, Sean Ji, Gigi Lo, Bryan Cheung and Ting Wang, registered foreign lawyer (New York, USA) Haiyun Chen, trainee solicitor Tiger Chan, and legal assistants Tiffany Chan, Jessica Lu and Olivia Kong.

Legal manager Marine Jin led Herbert Smith Freehills Kewei Joint Operation’s Alternative Legal Services business to provide high-efficiency solutions for verification and other document-intensive processes during the offering, assisted by legal analysts Chloe Hu, Jarros Fang, Chunqin Li and Ling Sun.

科笛集团是一家专注于皮肤学的研发型生物制药公司，侧重于广泛皮肤病治疗及护理治疗领域，包括局部脂肪堆积管理药物、毛发疾病及护理、皮肤疾病及护理以及表皮麻醉。科笛集团于2023年6月12日上市。

史密夫斐尔香港办公室合伙人艾迈修(Matt Emsley)表示：“科笛集团是一家领先的生物医药公司，我们很高兴助力其成功在联交所上市。衷心向科笛集团、独家保荐人和整体协调人表示祝贺，并祝愿他们不断取得成功。”

史密夫斐尔香港办公室合伙人(高级注册外国律师)谢守德(Stanley Xie)表示：“我们要向客户们表示衷心感谢，感谢他们所给予的信任，很高兴能够与他们就全球资本市场交易进行合作。”

史密夫斐尔在为保荐人和承销人就香港IPO上市提供法律服务方面处于市场领先地位。在过去两年里，本所为超过20个联交所IPO上市交易提供法律服务。

合伙人艾迈修、合伙人(高级注册外国律师*)谢守德以及合伙人(高级注册外国律师)孔瑾(Jin Kong)率领律师团队为此次上市的独家保荐人和整体协调人提供法律服务。主要团队成员包括林苡萱(Registered Foreign Lawyer)、高美诗(Senior Associate)、王令轩(Associate)、季晓源(Associate)、卢淑妍(Associate)、张皓阳(Associate)、王婷(Associate)、陈海韵(Registered Foreign Lawyer)、陈旭聪(Trainee Solicitor)、陈可宜 (Legal Assistant)、卢嘉铮(Legal Assistant)和孔德馨(Legal Assistant)。

金燊(Legal Manager)率领的科伟史密夫斐尔联营办公室替代性法律服务(ALT)联合团队在上市项目期间为招股书验证及其他文件密集型工作提供高效率的解决方案。胡彦珽(Legal Analyst)、方夹心(Legal Analyst)、李纯沁(Legal Analyst)和孙泠(Legal Analyst)提供支持。

*In application process 待完成注册